Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
polypharm.net

See what CB Insights has to offer

Founded Year

1980

Stage

Acquired | Acquired

About Poly Pharmaceuticals

POLY Pharmaceuticals is focused on developing and marketing branded, generic, and OTC pharmaceutical products. This remains our focus today. Poly markets a broad range of health care products for conditions such as cough, cold, allergy, sinusitis, pain relief, and urological health.On October 21st, 2021, Poly Pharmaceuticals was acquired by ADDvise. The terms of the transaction were not disclosed.

Poly Pharmaceuticals Headquarter Location

2720 Cullom Blvd.

Owens Cross Roads, Alabama, 35763,

United States

Latest Poly Pharmaceuticals News

Hepatic Encephalopathy Market Market Size, Share – Segmented by Products, Usability, Application, End Users, and Geography, Trends and Forecast 2027

Aug 24, 2021

Search jobs 24-Aug-2021 Hepatic Encephalopathy Market Market Size, Share – Segmented by Products, Usability, Application, End Users, and Geography, Trends and Forecast 2027 Global Hepatic Encephalopathy Market, by Drug Class (Laxatives, L-aspartate, Antibiotics, L-aspartate and others), by Route of Administration (Oral, Rectal and Intravenous), by Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies,), and by Region (Latin America, Europe, Asia Pacific, North America, Africa, and Middle East). In 2020, the market is expected to be worth US$ 355.4 million, with a CAGR of 5.3 percent during the forecast period (2020-2027). The increasing prevalence of various risk factors such as hepatitis C and hepatic cirrhosis among the population is likely to boost the worldwide hepatic encephalopathy market growth. According to the CMAJ Open journal: 2018, the prevalence of liver cirrhosis in the Canadian population is predicted to rise due to increased incidence of hepatitis C and non-alcoholic fatty liver disease. In Canada, over 30% of the population suffers from liver disease. Market participants are engaged in inorganic activities such as acquisitions, which are projected to broaden product portfolios and enhance company positions in the global market. Ferring Pharmaceuticals Inc., for example, purchased Rebiotix Inc., a clinical-stage biotechnology company, in 2018. This merger brought together two healthcare firms that are dedicated to researching and understanding the human micro biome in order to develop new treatments for patients. Impact of Coronavirus (COVID – 19) Pandemic: The global hepatic encephalopathy market is projected to be slowed by the COVID-19 pandemic. The majority of individuals suffering from significant liver damage require hepatic encephalopathy treatment, according to the National Center for Biotechnology Information (NCBI), and treatment may be delayed owing to the pandemic. Although, due to the lack of antibiotics, laxatives, and other medications, as well as erratic supply and transportation of medicine during the COVID-19 pandemic, the treatment of severe liver damage patients is postponed or even cancelled. Furthermore, the COVID-19 pandemic has disrupted the global drug supply, according to the US Food and Drug Administration (FDA), due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labor force, and restrictions on import and export activities, as well as travel. Antibiotic production has long been a particularly affected. Clinical studies for the development of novel medications for hepatic encephalopathy are projected to fuel growth of the worldwide hepatic encephalopathy market throughout the forecast period, according to key competitors. Mallinckrodt Pharmaceuticals, for example, conducted clinical trials in 2019 for MNK-6105 (ornithine phenylacetate) intravenous and MNK-6106 (ornithine phenylacetate) oral drugs to prevent chronic hepatic encephalopathy recurrence. Currently, the trial is in its third phase. Key Takeaways: Due to expansion in promising markets, particularly in Europe, the worldwide hepatic encephalopathy market is predicted to increase at a CAGR of 5.3 percent over the projected period (2020-2027). North America accounted for the major share of the market. The worldwide hepatic encephalopathy market is predicted to rise due to the rising availability of lactulose for the treatment of hepatic encephalopathy. For example, in April 2017, Cumberland Pharmaceuticals, a specialty pharmaceutical company based in the United States, and Poly Pharmaceuticals Inc., a privately held specialty pharmaceutical company based in the United States, signed an agreement to promote the Kristalose (lactulose solution for the treatment of hepatic encephalopathy) developed by Poly Pharmaceuticals Inc. in the United States. Kristalose’s present sales will be increased in the United States as a result of this multi-year co-promotion collaboration. Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2596 Hepatic Encephalopathy Market – Competitive Landscape Key players functioning in the global prosthetic liners market consists of ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd. Main points in Hepatic Encephalopathy Market Report Table of Content Chapter 1 Industry Overview 1.5 Global Hepatic Encephalopathy Market Size Analysis from 2021 to 2027 11.6 COVID-19 Outbreak: Hepatic Encephalopathy Industry Impact Chapter 2 Global Hepatic Encephalopathy Competition by Types, Applications, and Top Regions and Countries 2.1 Global Hepatic Encephalopathy (Volume and Value) by Type 2.3 Global Hepatic Encephalopathy (Volume and Value) by Regions Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.2 Regional Production Market Analysis Chapter 4 Global Hepatic Encephalopathy Sales, Consumption, Export, Import by Regions (2016-2021) Chapter 5 North America Hepatic Encephalopathy Market Analysis Chapter 6 East Asia Hepatic Encephalopathy Market Analysis Chapter 7 Europe Hepatic Encephalopathy Market Analysis Chapter 8 South Asia Hepatic Encephalopathy Market Analysis Chapter 9 Southeast Asia Hepatic Encephalopathy Market Analysis Chapter 10 Middle East Hepatic Encephalopathy Market Analysis Chapter 11 Africa Hepatic Encephalopathy Market Analysis Chapter 12 Oceania Hepatic Encephalopathy Market Analysis Chapter 13 South America Hepatic Encephalopathy Market Analysis Chapter 14 Company Profiles and Key Figures in Hepatic Encephalopathy Business Chapter 15 Global Hepatic Encephalopathy Market Forecast (2021-2027) Chapter 16 Conclusions About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Poly Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Poly Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.